Avanos Medical (NYSE:AVNS) Issues FY 2026 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.900-1.100 for the period, compared to the consensus estimate of 1.030. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $704.7 million.

Analysts Set New Price Targets

A number of brokerages have weighed in on AVNS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Avanos Medical Trading Down 1.6%

AVNS opened at $15.22 on Tuesday. The firm has a 50 day simple moving average of $12.86 and a 200 day simple moving average of $12.02. Avanos Medical has a fifty-two week low of $9.30 and a fifty-two week high of $16.63. The company has a market cap of $706.33 million, a price-to-earnings ratio of -1.49 and a beta of 1.09. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36.

Avanos Medical (NYSE:AVNS) last issued its earnings results on Tuesday, February 24th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.24 by $0.05. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. The company had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.70 million. During the same quarter in the previous year, the company posted $0.43 EPS. The business’s revenue for the quarter was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. On average, sell-side analysts anticipate that Avanos Medical will post 1.32 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC increased its stake in Avanos Medical by 312.4% in the third quarter. Millennium Management LLC now owns 896,242 shares of the company’s stock valued at $10,361,000 after purchasing an additional 678,898 shares in the last quarter. Armistice Capital LLC grew its holdings in shares of Avanos Medical by 22.8% in the 3rd quarter. Armistice Capital LLC now owns 2,500,000 shares of the company’s stock valued at $28,900,000 after buying an additional 464,000 shares during the period. Ameriprise Financial Inc. increased its position in shares of Avanos Medical by 356.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 591,181 shares of the company’s stock valued at $6,834,000 after buying an additional 461,706 shares in the last quarter. Citadel Advisors LLC increased its position in shares of Avanos Medical by 212.0% in the 3rd quarter. Citadel Advisors LLC now owns 574,104 shares of the company’s stock valued at $6,637,000 after buying an additional 390,082 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in Avanos Medical by 190.4% during the 2nd quarter. AQR Capital Management LLC now owns 560,052 shares of the company’s stock worth $6,855,000 after buying an additional 367,188 shares during the period. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.